| Diabetes Mellitus, Non-Insulin-Dependent
Humalog 75/25 vs Onglyza
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Humalog vs Onglyza with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOnglyza has a higher rate of injection site reactions vs Humalog based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Onglyza but not Humalog, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Humalog
Onglyza
At A Glance
SC injection
Twice daily
Insulin analog
Oral
Daily
DPP-4 inhibitor
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Diabetes Mellitus, Non-Insulin-Dependent Inject SC within 15 minutes before a meal into abdominal wall, thigh, upper arm, or buttocks; typically dosed twice daily; individualize dose based on metabolic needs and blood glucose monitoring results.
Diabetes Mellitus, Non-Insulin-Dependent 2.5 mg or 5 mg orally once daily taken regardless of meals; reduce to 2.5 mg once daily for eGFR <45 mL/min/1.73 m2 or when coadministered with strong CYP3A4/5 inhibitors.
Contraindications
- During episodes of hypoglycemia
- Previous hypersensitivity reactions to HUMALOG Mix75/25 or any of its excipients
- History of serious hypersensitivity reaction to saxagliptin or any ingredient in ONGLYZA (anaphylaxis, angioedema, or exfoliative skin conditions)
Adverse Reactions
Most common Hypoglycemia
Serious Severe anaphylaxis, hypokalemia
Postmarketing Lipodystrophy, localized cutaneous amyloidosis, injection site reactions, peripheral edema, weight gain, anti-insulin antibody formation
Most common (>=5%) Upper respiratory tract infection, urinary tract infection, headache
Serious Pancreatitis, heart failure, hypoglycemia with insulin or insulin secretagogues, hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid
Postmarketing Pancreatitis, anaphylaxis, angioedema, exfoliative skin conditions, rhabdomyolysis, severe and disabling arthralgia, bullous pemphigoid
Pharmacology
Insulin analog; regulates glucose metabolism by stimulating peripheral glucose uptake by skeletal muscle and fat and inhibiting hepatic glucose production, while also inhibiting lipolysis and proteolysis and enhancing protein synthesis.
Saxagliptin is a competitive DPP-4 inhibitor that slows the inactivation of incretin hormones (GLP-1 and GIP), increasing their bloodstream concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 diabetes mellitus.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Humalog
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (9/12)
Onglyza
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Humalog
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (6/8)
Onglyza
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (7/8)
Humana
Humalog
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (2/3) · Qty limit (0/3)
Onglyza
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Humalog.
No savings programs available for Onglyza.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
HumalogView full Humalog profile
OnglyzaView full Onglyza profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.